Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response.
- Author:
Byong Su JANG
1
;
Hyeran KIM
;
Shinn Won LIM
;
Ki Won JANG
;
Doh Kwan KIM
Author Information
1. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. paulkim@skku.edu
- Publication Type:Clinical Trial ; Original Article
- Keywords:
S100B;
Major depressive disorder;
Antidepressant;
Response;
Neuroplasticity
- MeSH:
Antidepressive Agents;
Biomarkers;
Depression;
Depressive Disorder, Major*;
Humans;
Neuronal Plasticity
- From:Psychiatry Investigation
2008;5(3):193-198
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders. METHODS: Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared. RESULTS: There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders. CONCLUSION: The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants.
